Nicotine Analogue Concentrations Deviate From Labels

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

TUESDAY, Aug. 13, 2024 -- There are discrepancies between labeled and measured concentrations of nicotine analogues in electronic cigarettes and e-cigarette liquids, according to a research letter published online Aug. 7 in the Journal of the American Medical Association.

Hanno C. Erythropel, Ph.D., from Yale University in New Haven, Connecticut, and colleagues quantified constituents of e-cigarette products containing nicotine analogues to assess product consistency. The analysis included nine available flavors of product 1 labeled as containing 5 percent 6-methylnicotine (6MN) and two flavors of product 2 at four concentrations of nicotinamide (0, 12, 24, and 36 mg/mL) that were purchased between November 2023 and February 2024 from three major online retailers.

The researchers found that 6MN presence was confirmed in all product 1 flavors. Both nicotinamide and 6MN were detected in product 2 samples labeled as containing nicotinamide (six of eight). No sample contained nicotine. Product 1 was labeled as containing 5 percent 6MN (50 mg/g), but the analysis showed it only contained 5.8 to 6.3 mg/g (87 to 88 percent less than labeled). In product 2, samples contained nicotinamide contents 7 to 46 percent less than as labeled. Although product 2 labels did not list 6MN as an ingredient, 6MN was detected (0.06 to 0.17 mg/g) when nicotinamide was present. Product 1 samples contained only the (S)-6MN stereoisomer, which previous research showed is more potent and addictive than the (R) form. Product 1 samples all contained the artificial sweetener neotame (0.20 to 0.86 mg/g) and the synthetic coolant 2-isopropyl-N-2,3-trimethylbutyramide (WS-23; 4.34 to 16.39 mg/g) plus various flavorants, whereas product 2 samples did not contain sweeteners or coolants.

"With e-cigarettes increasingly considered for smoking cessation, the advent of nicotine analogue-containing products with unknown health risks raises concern," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords